Correction to: The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan
本文未提供摘要,请点击“查看全文”查看完整内容。